Histogen price target lowered to $2.00 from $5.00 at Canaccord

Canaccord lowered the firm’s price target on Histogen to $2.00 from $5.00 and keeps a Buy rating on the shares. The analyst said with the termination of the HST-003 program, the company will concentrate all efforts on developing its early-stage pan-caspase inhibitors: Emricasan, CTS-2090, and CTS-2096. Canaccord notes Histogen is also seeking partners or acquirers for its human multipotent cell conditioned media (CCM) and human extracellular matrix (hECM).